Philippe Berthon
Directeur Général chez Aurgalys SAS
Profil
Dr. Philippe Berthon is Founder & Chief Executive Officer at Aurgalys SAS.
He is on the Board of Directors at France Biotech Association.
Previously, Dr Berthon was Chief Executive Officer of Vaxon-Biotech (2004-2008), a company developing cancer immunotherapeutic products at late clinical development stages.
He founded UroGene in 1998, was CEO then President & CSO.
UroGene was dedicated to urological diseases including cancer and incontinence, raised a total of €25M venture capital money, and was traded off to Groupe Pierre Fabre early 2005.
Prior to these appointments, Dr Berthon was co-founder and CEO of CeRePP at Hospital Saint Louis, Paris, from 1995-1999; senior post-doctoral fellow at the Cancer Research Unit, University of York, UK, for 3 years; and research fellow at Paris VI University for 5 years.
Dr Berthon co-authored more than 50 peer-reviewed international publications, received his PhD in Reproduction Physiology at Paris VI University, and graduated from Challenge+ Business and Administration program, HEC School of Management, Jouy en Josas, France.
Philippe Berthon is member of France Biotech, of Société Française des Analystes Financiers (SFAF) and Association des Analystes Conseil en Investissement Financier et Transmission d’Entreprises (ACIFTE).
He received his doctorate degree from Université Pierre et Marie Curie.
Postes actifs de Philippe Berthon
| Sociétés | Poste | Début |
|---|---|---|
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Directeur/Membre du Conseil | 06/08/2010 |
Aurgalys SAS
 Aurgalys SAS Investment ManagersFinance Aurgalys SAS provides investment research. The private company is based in Soisy sur Ecole, France. The French company was founded by Philippe Berthon. Philippe Berthon has been the CEO since incorporation. | Directeur Général | - |
Anciens postes connus de Philippe Berthon
| Sociétés | Poste | Fin |
|---|---|---|
Urogene SA
 Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | President | - |
Formation de Philippe Berthon
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
| Université Pierre et Marie Curie | Consumer Services |
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Commercial Services |
Aurgalys SAS
Aurgalys SAS Investment ManagersFinance Aurgalys SAS provides investment research. The private company is based in Soisy sur Ecole, France. The French company was founded by Philippe Berthon. Philippe Berthon has been the CEO since incorporation. | Finance |
